| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A portion of amino acids 234-263 from the human protein was used as the immunogen for the SLC29A1 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
SLC29A1 Antibody / Solute carrier family 29 member 1 / ENT1 is an antibody targeting SLC29A1, raised in Rabbit for protein detection and localization studies where these specifications are required.
Key elements and design rationale
- Target: SLC29A1.
- Antibody identity: Polyclonal (rabbit origin); Rabbit Ig.
- Conjugate/label: Unconjugated (affects detection chemistry and multiplex compatibility).
- Format: Purified.
- Species reactivity: Human, Mouse.
- Listed applications: WB (refer to on-page specifications for application-specific guidance).
Biological background
SLC29A1 (Solute carrier family 29 member 1), also known as the Equilibrative nucleoside transporter 1 (ENT1), is a protein that plays a role in the transport of nucleosides across cell membranes. Nucleosides are essential components of DNA and RNA, and their transport into cells is crucial for various cellular processes, including DNA replication and protein synthesis. Recent research has also suggested that SLC29A1 protein may play a role in regulating the immune response and inflammation. Studies have shown that altered expression of SLC29A1 protein can lead to dysregulation of immune cells, contributing to inflammatory disorders and autoimmune diseases. Additionally, SLC29A1 protein has been implicated in cancer progression. Studies have shown that increased expression of SLC29A1 protein is associated with enhanced cell proliferation and survival in various cancer types. This suggests that targeting SLC29A1 protein could be a promising therapeutic strategy for cancer treatment.
Research relevance and current trends
- Comparative expression profiling across cell types, tissues, or perturbations (e.g., drug treatment, genetic editing, or differentiation).
- Subcellular localization and trafficking studies, including co-localization with pathway markers in microscopy-based assays.
- Integration of protein-level measurements with transcriptomics or proteomics to relate abundance to regulation and phenotype.
Common research applications
- Western blotting: researchers commonly compare relative signal levels across conditions and use appropriate negative/positive controls for interpretation.
Interpretation should account for antibody-dependent factors such as epitope accessibility, isoforms, and sample preparation differences across workflows.
Notes for experimental interpretation
- Isoforms and PTMs: many targets have multiple isoforms and post-translational modifications that can shift apparent signal or localization; interpret bands/signals accordingly.
- Epitope context: binding can depend on protein conformation and sample processing; region information in the title/immunogen can help anticipate what may be detected.
- Species differences: predicted or validated reactivity may vary by ortholog sequence and sample context; confirm in your model system.
- Control concepts: include negative controls (no-primary/isotype), and where possible genetic controls (KO/KD) or independent antibodies to strengthen conclusions.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
